Nitazene opioids and the heart: Identification of a cardiac ion channel target for illicit nitazene opioids
2024

Nitazene Opioids and the Heart: A Cardiac Ion Channel Target

publication Evidence: moderate

Author Information

Author(s): Hancox Jules C., Wang Yibo, Copeland Caroline S., Zhang Henggui, Harmer Stephen C., Henderson Graeme

Primary Institution: University of Bristol

Hypothesis

Do nitazene opioids inhibit the hERG potassium channel, potentially leading to cardiac issues?

Conclusion

Nitazene opioids are predicted to inhibit the hERG channel, suggesting a risk for cardiac arrhythmias.

Supporting Evidence

  • All nitazenes were predicted to inhibit hERG with low μM IC50 values.
  • Predictions indicated a potential for proarrhythmic hERG block by nitazene opioids.
  • Previous studies have linked methadone and other opioids to QT prolongation and Torsades de Pointes.

Takeaway

Nitazene opioids might mess with your heart's electrical signals, which can be dangerous.

Methodology

Machine-learning tools were used to evaluate the interaction of five nitazene compounds with the hERG potassium channel.

Potential Biases

The predictions require validation through in vitro studies, and the study may not account for all potential drug interactions.

Limitations

The study only focused on hERG and did not evaluate potential interactions with other cardiac ion channels.

Digital Object Identifier (DOI)

10.1016/j.jmccpl.2024.100118

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication